Does Medicare Cover Wegovy, Ozempic, and GLP-1 Weight Loss Drugs?

The GLP-1 drugs, semaglutide, tirzepatide, and their branded forms including Ozempic, Wegovy, Mounjaro, and Zepbound, are among the most discussed medications in medicine today. For Medicare beneficiaries who are asking whether Medicare pays for these drugs, the answer depends on something specific and important: what the drug is prescribed for. The same molecule can be covered or not covered based solely on its indicated use, and understanding this distinction could save you from an unexpected pharmacy bill or help you find coverage you did not know was available.

Bryce's Take

The GLP-1 question comes up in almost every call I take now. The short version: if you have type 2 diabetes and your doctor prescribes semaglutide for blood sugar management, Part D covers it. If you want it for weight loss and do not have diabetes, standard Part D does not cover it, though a growing number of Advantage plans have added obesity drug coverage. This area is changing quickly and the right answer depends on what is available in your area right now.

The Part D exclusion for weight loss drugs

Medicare Part D by statute excludes coverage for agents when used for anorexia, weight loss, or weight gain. This exclusion has been in federal law since Medicare Part D was created in 2006 and applies regardless of how effective the medication is, how medically significant the weight loss is, or how strongly your physician recommends it. Wegovy (semaglutide at higher dose) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management. Because their indicated use is weight loss, Medicare Part D does not cover them for that purpose.

The Ozempic situation: diabetes versus weight loss

Ozempic is semaglutide at a lower dose, FDA-approved for type 2 diabetes management. When prescribed for type 2 diabetes, Ozempic is covered under Medicare Part D as an antidiabetic medication. The same drug molecule, at a higher dose branded as Wegovy, prescribed for weight loss rather than diabetes, is not covered. If you have type 2 diabetes and your physician prescribes semaglutide for blood sugar management, Part D coverage applies. If you do not have type 2 diabetes and are prescribed the medication for weight loss, Part D does not cover it. The prescription indication and diagnosis code determine coverage, not the molecule.

Cardiovascular risk reduction: an evolving area

The SELECT trial published in 2023 demonstrated that semaglutide reduces major cardiovascular events in people with obesity and established cardiovascular disease, independent of its weight loss effects. CMS has been evaluating whether this cardiovascular indication could support Part D coverage. As of 2025, this coverage expansion has not been implemented uniformly. Some beneficiaries and advocacy organizations have pushed for coverage of GLP-1 drugs for cardiovascular risk reduction in people with established heart disease, and this area continues to evolve. Check with your physician and plan for the most current coverage status.

Medicare Advantage supplemental coverage for obesity drugs

Starting in plan year 2024, CMS allowed Medicare Advantage plans to offer obesity drug coverage as a supplemental benefit beyond Original Medicare. This is optional for plans, they are not required to offer it. A growing number of Medicare Advantage plans have added this coverage, but adoption is far from universal, and the drugs covered, the formulary tiers, and the cost-sharing vary significantly between plans. If you are already using a GLP-1 drug for weight loss and are Medicare-eligible, comparing Medicare Advantage plans specifically for obesity drug coverage is worthwhile. Use the Medicare Plan Finder and review each plan's formulary directly.

Questions about whether a specific medication is covered under your plan?

Formulary coverage questions, especially for newer drugs, are exactly the kind of thing worth checking before you fill a prescription. I can help you understand what your plan covers.

Book a Free Call

The out-of-pocket reality without coverage

Without Medicare Part D or Medicare Advantage coverage, GLP-1 drugs for weight loss cost $800 to $1,500 per month or more at retail price. Manufacturer discount programs and coupon services like GoodRx can reduce costs for non-Medicare patients, but federal law generally prohibits Medicare beneficiaries from using manufacturer co-pay cards for covered drugs (though for non-covered drugs the situation is more nuanced). This cost barrier is exactly why advocacy groups have been pushing for Medicare Part D expansion to cover obesity treatment.

What to ask your physician and plan

If you want GLP-1 coverage, ask your physician whether you have any covered indication (type 2 diabetes, cardiovascular disease). Ask your Medicare Advantage plan specifically whether it covers any GLP-1 medications for weight management and request the plan's current drug formulary. If you are comparing Medicare Advantage plans during AEP, specifically filter for obesity drug coverage if this is a priority. The landscape is changing faster than most comparison tools reflect, making direct plan contact the most reliable way to get current information.

Frequently asked questions

Is Mounjaro (tirzepatide) covered by Medicare?

Mounjaro, FDA-approved for type 2 diabetes, is covered under Medicare Part D for diabetes management. Zepbound, the same tirzepatide molecule at a weight-management dose, is FDA-approved for obesity and is not covered by standard Part D for weight loss purposes. The coverage distinction is the same as Ozempic versus Wegovy.

Can I get a Medicare Advantage plan that covers Wegovy?

Some Medicare Advantage plans began offering obesity drug coverage as an optional supplemental benefit starting in 2024. These plans are not available everywhere, and coverage details vary. During the Annual Enrollment Period, compare plans specifically for obesity drug formulary coverage if this is a priority for you.

Will Medicare ever cover weight loss drugs?

Legislation has been proposed in Congress to require Medicare Part D coverage for FDA-approved obesity treatments. As of 2025, no such law has passed, though the political and clinical case for coverage has strengthened following cardiovascular outcome trial data. The situation may change in future plan years.

My doctor says I need this medication medically. Can I appeal a denial?

For drugs excluded by statute (like weight loss medications under Part D), plan-level appeals and formulary exceptions do not override the statutory exclusion. If your physician believes you have a covered indication (such as type 2 diabetes), work with them to document the appropriate diagnosis. If the drug is being denied for a covered indication, a formal appeal is appropriate.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.